FROM:
Description
e-therapeutics plc (“ETX”) combines computation and RNAi to discover and develop life-transforming medicines. The computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. The Company is progressing a pipeline of highly differentiated RNAi therapies across a variety of therapeutic areas with high unmet need.
READ MORE >
Company Snapshot
Status
Live
Dealing Restrictions
None
Price
15.00
Ticker
ETX
Class
ORD
Settlement
CREST
Industry
Professional, scientific & technical services
COUNTRY
United Kingdom
Company Number
04304473
ISIN
GB00B2823H99
Currency
GBX
COMPANY INSIGHTS
Incorporated
15 October 2001
Securities in Issue
777,002,15
Market Cap
£117m
Trading Results
| Date | Quantity | Mid. Price GBX |
|---|---|---|
| 08/07/2024 | 45834 | 15 |
| 04/07/2024 | 4166 | 10 |
| 24/06/2024 | 440240.0 | 9.95 |
| 24/06/2024 | 50000.0 | 9.95 |
| 17/06/2024 | 1604.0 | 9.95 |
key features of trading on jp jenkins
BUYERS
Buyers decide on the price per share they’re willing to pay, and the number of shares they wish to buy.
SELLERS
Sellers decide the minimum price they’ll accept for their shares.
IMPORTANT INFORMATION
This instruments from e-therapeutics plc is not traded on an investment exchange such as the London Stock Exchange or the Alternative Investment Market. Consequently, transactions involving these instruments may be infrequent, potentially causing a delay between when you give instructions to buy or sell and when your order is executed. Additionally, it can be challenging to accurately assess the value of your investment.
Download Area
| Documents | ||
| Annual Report 2023 | 5.09 MB |
Description
e-therapeutics plc (“ETX”) combines computation and RNAi to discover and develop life-transforming medicines. The computational platform allows ETX to discover better medicines faster through generation of novel insights and increased automation across all stages of drug development. The Company is progressing a pipeline of highly differentiated RNAi therapies across a variety of therapeutic areas with high unmet need.
READ MORE >
Latest News
SEE MORE NEWS ARTICLES >
e-therapeutics plc Management Information
Ali Mortazavi
Chief Executive Officer
Lord Prior of Brampton
Non-Executive Chairman
Professor Trevor Jones CBE
Non-Executive Director
Michael Bretherton
Non-Executive Director
Laura Roca-Alonso, PHD
Chief Operating and Business Officer
Alan Whitmore
Chief Scientific Officer
Timothy Bretherton
Chief Financial Officer & Company Secretary
Jeremy Punnett
Non-Executive Director
e-therapeutics plc Contact Details
Address
4 Kingdom Street,
London,
England,
W2 6BD
London,
England,
W2 6BD
EMAIL
contact@etherapeutics.co.uk
phone
+44 (0) 20 4551 8888
Contacts
Registrars
Neville Registrars Limited
Neville House
18 Laurel Lane
Halesowen
West Midlands
B63 3DA
www.nevilleregistrars.co.uk
Neville House
18 Laurel Lane
Halesowen
West Midlands
B63 3DA
www.nevilleregistrars.co.uk
+44 (0) 121 585 1131
TRANSACTING ON JP JENKINS
‘Trading‘ on JP Jenkins is done via a matched bargain facility, this means that on instruction from your ‘Broker’ we will endeavour to match your shares against other buyer(s) or seller(s) who are also looking to transact. Requests to trade are performed on an availability basis, should an instruction be cancelled, altered or amended in anyway by an instruction from your broker then it shall lose its active place in the queue and reset to the end of list. JP Jenkins receives orders from brokers electronically via a FIX message or should your broker not have a FIX connection to our platform via telephone. If you do not have a UK registered stockbroker you will find a list of brokers that we have worked with to download here. You will also find a list of UK brokers at the bottom of this page and their contact details should you need to appoint one. JP Jenkins can ONLY take instruction to transact from a UK-registered stockbroker and cannot offer investment advice into companies displayed on our website. If you are unsure about trading please consult a financial advisor or wealth manager to assist you in determining what is right for you
